Please assess the completion status of the following clinical trial:

Trial Title: Cryobiopsy Study to Assess Drug Distribution in Subjects With Suspected Interstitial Lung Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* 18 and above years of age inclusive, at the time of signing the informed consent.~* Subjects with suspected ILD listed for TBCB for clinical reasons following review by the ILD services at University College London Hospitals (UCLH) in whom diagnosis has remained unclear following radiological and clinical assessment.~* A subject with a clinical abnormality or laboratory parameter(s) which is/are not specifically listed in the inclusion or exclusion criteria, outside the reference range for the population being studied, may be included only if the investigator in consultation with the Medical Monitor agree and document that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures.~* Male or Female.~* Capable of giving signed informed consent which includes compliance with the requirements and restrictions.~Exclusion Criteria:~* Subjects who have a known drug allergy or other contra-indication to ipratropium bromide.~* Known hypersensitivity to atropine or ipratropium bromide or any other known drug allergies that, in the opinion of the investigator or GlaxoSmithKline (GSK) Medical Monitor, contraindicates their participation.~* As a result of the medical history, physical examination or screening investigations, the physician responsible considers the subject unfit for the study.~* The subject is unable or unwilling to perform study assessments and procedures correctly.~* Subjects with a recognized co-existing respiratory disorder (other than ILD) that in the opinion of the investigator would confound the study outcomes.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Subjects with suspected fibrotic ILD (Type: None): Eligible subjects will receive nebulized ipratropium bromide 500 mcg for 10 minutes. The subjects will be sedated for bronchoscopic procedure as per routine practice for subjects having bronchoscopy. Cryobiopsy samples for this study will be taken after samples required for diagnosis has been taken and it is safe to do so. One to three endobronchial forceps biopsy samples will be taken from up to 5 subjects to allow comparison of proximal and distal drug distribution.

Based on this trial design, predict the completion outcome and termination type (if applicable).